Loading clinical trials...
Loading clinical trials...
Ibrutinib Monotherapy in Early Stage Chronic Lymphocytic Leukemia (CLL) Without IWCLL/NCI-WG 2008 Treatment Indications But With High-Risk Features for Disease Progression
Conditions
Interventions
Ibrutinib
Locations
1
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
May 23, 2018
Primary Completion Date
August 2, 2024
Completion Date
August 2, 2024
Last Updated
September 2, 2025
NCT06846671
NCT07218341
NCT07030400
NCT07277231
NCT05006716
NCT06859424
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions